‘The next four weeks will be better’: Jim Cramer sees reasons to be more positive on stocks and gives these 2 names his stamp of approval – Yahoo Finance

Unhappy with the state of the portfolio after miserable 2022 stock market action? You are probably far from alone. Most investors have struggled to make headway in this year’s ongoing bear market, which has provided only short periods of relief.
That said, with the year’s end getting ever nearer, Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, thinks the bears are showing signs of exhaustion and this spells good news for battered investors.
“You’ve got to adjust your mindset to a world where the bears are finally in retreat, because I’m betting the next four weeks will be much better than what we’ve come to be used to,” Cramer said.
With this in mind, let’s take a closer look at two stocks that recently received Cramer’s nod of approval in his ‘lightning round’ segment. According to TipRanks’ database, Cramer is not alone in thinking these tickers are ripe for the picking; both are rated as Strong Buys by the analyst consensus. Here are the details.
MP Materials (MP)
The first name we’ll look at is a “winner,” according to Cramer. MP Materials is a North American-based miner of rare earth materials. Its deposit-rich Mountain Pass mine in California is the United States’ largest rare earth mine and processing facility and provides the company with a ~15% global market share in upstream rare earth manufacturing.
Its production is mainly focused on Neodymium-Praseodymium (NdPr), a rare earth element utilized in high-strength permanent magnets that drive the traction motors used in electric vehicles, drones, wind turbines, robotics, and other cutting-edge motion technologies.
Being able to produce much-needed components used in segments gaining adoption should be a recipe for success, and the company built on the rise in the realized price of rare earth oxide in its latest earnings report – for Q3.
Despite COVID-19 lockdowns in China and global economic headwinds, which accounted for a sequential decline in NdPr prices, average prices were up significantly year-over-year, underscoring the ongoing robust demand for NdPr.
Revenue rose by 24.8% year-over-year to $124.45 million, beating the Street’s call by $6.73 million. The increase in revenues resulted in a 34% y/y uptick in adjusted EBITDA, which reached $91.4 million. As a result, Adj. EPS of $0.36, also beat the Street’s forecast of $0.30.
So, Cramer thinks MP is a “winner” and so does BMO analyst Robin Fiedler.
“MP is a rare earth pureplay with a tier-1 asset amid scarce alternatives. We view MP’s unique and multi-faceted vertical-integration growth and Chinese supply chain circumvention strategy as compelling and thus able to stomach near-term price and expansion risks,” the analyst said. “We believe at current levels risk-reward is attractive considering our assessment of mid- to long-term vertical integration upside and the potential for various legislative ‘wins’ next year.”
Accordingly, Fiedler rates MP shares an Outperform (i.e. Buy) while his $50 price target makes room for 12-month gains of 53%. (To watch Fiedler’s track record, click here)
Fiedler’s take on MP is bullish – and he’s far from the only bull on the stock. MP has 7 recent analyst reviews, with 6 Buys and 1 Hold for a Strong Buy consensus rating. The shares are priced at $32.68 and their $44.93 average price target implies ~37% one-year upside potential. (See MP Materials stock forecast on TipRanks)
ICON plc (ICLR)
“I like it. It’s a very inexpensive stock.” That is Cramer’s short and succinct explanation for backing the next company we’ll look at.
Icon is a big name in the world of clinical research organizations (CROs). That is, the company helps pharma, biotech, and other research labs get their work done. It is one of the sector’s biggest names offering across the board services. These include everything from strategic development, program analysis, and assistance in compound selection to patient recruitment and retention, site monitoring, and data management, amongst others.
Icon has been through some big changes over the past year and a half. In July 2021, the company closed its acquisition of contract research company PRA Health Sciences in a deal worth ~$12 billion, creating what it touts as the “world’s most advanced healthcare intelligence and clinical research organization.”
On the financials front, Icon’s latest statement was a success. In the Q3 report, the company generated revenue of $1.94 billion, coming in $10 million above Street expectations. Likewise, EPS of $1.94 beats the analysts’ forecast of $1.82. The company also reaffirmed its full year 2022 revenue and adj. EPS guidance.
Assessing the Q3 print, J.P. Morgan analyst Casey Woodring thinks the long-term thesis remains “intact” whilst highlighting the importance of the FRAH deal.
“We are encouraged by how the company has executed in 2022 and view the reiteration of the LT targets out to 2025 as a positive indicator of the overall health of the market and ICLR’s competitive positioning,” the analyst wrote. “We continue to view ICLR as a top-tier clinical CRO with a compelling financial profile that is more levered to large pharma during this time of smid biotech uncertainty along upside potential from new business wins as a result of the company’s scale and integrated capabilities from the PRAH deal.”
These comments underpin Woodring’s Overweight (i.e., Buy) rating, which is backed by a $265 price target. The implication for investors? Upside of ~22% from current levels. (To watch Woodring’s track record, click here)
Overall, ICON gets robust support from the Street; the ratings break down as 7 to 2 in favor of Buys over Holds and culminate in a Strong Buy consensus rating. The average target is slightly lower than Woodring’s objective; at $259, the figure suggests a one-year upside potential of ~20%. (See ICLR stock forecast on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Related Quotes
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common…
The doom and gloom brigade has been out in full force recently, persistently warning the economy is in a precarious state and that a recession next year is all but inevitable. Maybe so, but that doesn't necessarily mean the stock market is destined to follow suit. In fact, the J.P. Morgan Asset Management team expects 2023 will be a “bad year for the economy, a better year for markets.” “Our core scenario sees developed economies falling into a mild recession in 2023,” added Asset Management tea
It's an announcement that is somewhat like a thunderbolt in the automotive industry. Three months ago, Rivian, which aims to challenge Tesla in the race for electric vehicles, announced with fanfare a partnership with Mercedes-Benz to manufacture electric vans in Europe. For Rivian , it was a key partnership as the company encountered difficulties in increasing its production capacities.
Is there more pain ahead?
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Intel Corporation (INTC) and Advanced Micro Devices, Inc. (AMD).
Is China's zero-Covid strategy finally over? While most Western nations have prioritized a return to normal and an end to COVID pandemic restrictions, China was the standout for maintaining its strongly restrictive lockdown policies. But there is mounting evidence that Beijing is looking for a way to back off from the lockdowns – and Chinese policymakers appear to be edging toward reopening their economy. That’s good news for investors, as a pullback from the zero-COVID controls in such major ci
Brookfield Asset Management (NYSE: BAM) recently completed a unique stock split. Brookfield completed this split so that its investors would have direct exposure to its asset management business's dividend income and growth. CEO Bruce Flatt recently discussed the growth it has already locked up at a recent industry conference.
As FTX continues to be unwound, its new CEO is set to tell Congress at least five things he knows the company did with the money from clients and investors.
In this article, we will take a look at the 10 cheap small-cap stocks to buy before the next breakout. If you want to see more stocks in this selection, go to the 5 Cheap Small-Cap Stocks to Buy Before the Next Breakout. Some of the prominent large and mega-cap stocks in the world today used […]
Investors who bought the dip in Cathie Wood ‘s ARK Innovation exchange-traded fund have been punished this year. Shares of the fund, a pandemic-era favorite largely made up of unprofitable, growth-oriented technology companies, are down 63% this year. Investors have bailed out of growth stocks and other speculative assets en masse this year.
(Bloomberg) — A contrarian indicator of stock-market volatility is sending an encouraging sign for US equities in the coming weeks. Most Read from BloombergElon Musk Is Ruining Trump’s Presidential CampaignChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergySam Bankman-Fried Arrested in Bahamas as US Files FTX ChargesKeystone Has Leaked More Oil Than Any Other Pipeline in US Since 2010The Cboe Volatility Index, or VIX, fell int
GE HealthCare management is meeting with investors before it separates from General Electric in early January.
Binance endured $902 million of net outflows in the past 24 hours, according to data by Nansen.
Shares of Silvergate Capital (NYSE: SI) fell as much as 10.2%, once again, on Monday morning as the crypto industry continues to unearth new risks. This time, it's a U.S. investigation into Binance caught the industry off guard. Multiple news outlets reported this morning that the U.S. Department of Justice has an ongoing criminal probe into Binance, the world's largest crypto exchange.
Tesla Inc. stock on Monday ended at a fresh two-year low, going against broader market strength and as December losses look poised to match November's and October's double-digit declines.
Oracle shares were moving higher late Monday after the company posted better-than-expected financial results for its latest quarter. “Simply put, we had an outstanding quarter,” Oracle CEO Safra Catz said on a call with analysts. For the fiscal second quarter ended Nov. 30, Oracle (ticker: ORCL) posted revenue of $12.28 billion, up 18% from a year ago, or 25% adjusted for currency.
Devon Energy (DVN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
When income investors purchase a real estate investment trust (REIT), one of the things they hope is that the stock will perform well enough for the company to increase its quarterly dividend as the years go by, raising the investor’s annual yield. Usually, the dividend hikes are 3 to 5 cents per year, and investors are happy if they can get that on a steady basis. For example, a $1 dividend on a $25 stock that increases its dividend by 5 cents per year can turn a 4% yield into a 5% yield in abo
It may not be practical — at least for now.
Bank of Montreal (TSX: BMO)(NYSE: BMO) (the "Bank", "we" or "us") today announced the issue and sale of common shares pursuant to a public offering and a concurrent private placement for gross proceeds totaling approximately C$3.15 billion. This follows the announcement by the Office of the Superintendent for Financial Institutions ("OSFI") of its intention to increase the domestic stability buffer ("DSB") for Domestic Systemically Important Banks ("D-SIBs").

source